This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

Danaher is a diversified life sciences and diagnostics company with global operations. Its products and solutions support the biopharma industry in the development and production of therapies. Its Diagnostics segment provides clinical instruments, reagents, and consumables to hospitals, physicians' offices, and reference laboratories. Danaher was founded in 1984 by the Rales brothers, Steven and Mitchell. Through acquisitions, Danaher evolved from being a mortgage services company to become a life sciences tools company serving the biotech and diagnostics industry and applied markets. In March 2020, it acquired the GE Biopharma business and renamed it Cytiva. Danaher has continued to make acquisitions, including Aldevron in 2021 and Abcam in 2023. These acquisitions broadened its technology offerings and expanded its manufacturing capabilities.

Stocks were lower on Thursday. Earnings continue to drive sentiment, though investors are keeping an eye at all times on the Middle East. On the earnings front, software stocks led the move lower with renewed fears about the impact of AI on the industry. Also of note were higher oil prices that are the result of the war in Iran and the related impact on the Strait of Hormuz. After the close, however, some good news came in the form of a three-week extension of the ceasefire between Israel and Lebanon.